1. Home
  2. NVST vs ADPT Comparison

NVST vs ADPT Comparison

Compare NVST & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NVST

Envista Holdings Corporation

SELL

Current Price

$23.28

Market Cap

3.8B

Sector

Health Care

ML Signal

SELL

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

SELL

Current Price

$24.77

Market Cap

4.5B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
NVST
ADPT
Founded
2018
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
4.5B
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
NVST
ADPT
Price
$23.28
$24.77
Analyst Decision
Buy
Strong Buy
Analyst Count
15
9
Target Price
$28.69
★ $29.81
AVG Volume (30 Days)
★ 2.7M
2.3M
Earning Date
11-04-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 104.31
63.89
EPS
★ 0.56
N/A
Revenue
★ $2,566,500,000.00
$276,976,000.00
Revenue This Year
$5.80
$5.94
Revenue Next Year
$3.55
$22.42
P/E Ratio
$41.96
★ N/A
Revenue Growth
N/A
★ 54.77
52 Week Low
$18.77
$12.00
52 Week High
$30.42
$30.74

Technical Indicators

Market Signals
Indicator
NVST
ADPT
Relative Strength Index (RSI) 41.56 40.00
Support Level $22.69 $23.73
Resistance Level $23.94 $26.51
Average True Range (ATR) 0.58 1.44
MACD 0.13 -0.45
Stochastic Oscillator 57.63 8.42

Price Performance

Historical Comparison
NVST
ADPT

About NVST Envista Holdings Corporation

Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: